» Articles » PMID: 36841279

Efficacy of Indocyanine Green and Methylene Blue Mediated-photodynamic Therapy on Peri-implant Outcomes Among Diabetics with Peri-implant Mucositis

Overview
Publisher Elsevier
Date 2023 Feb 25
PMID 36841279
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to assess the efficacy of indocyanine green (ICG)-mediated versus methylene blue (MB)-mediated photodynamic therapy (PDT) as an adjunct to conventional mechanical debridement (MD) on the peri‑implant clinical, radiographic, microbiological, and immunological outcomes among diabetics with peri‑implant mucositis (pi-M).

Methods: For this 3-month follow-up study, diabetics having pi-M were randomly divided into 3 groups: group-I (n = 20) subjects received only MD; group-II (n = 20) participants received ICG-mediated adjunct PDT; and group-III (n = 20) subjects received MB-mediated adjunct PDT. Peri-implant clinical (i.e., plaque index [PI], bleeding on probing [BOP], probing depth [PD]), radiographic (crestal bone loss [CBL]), microbiological (Fusobacterium nucleatum [F. nucleatum], Tannerella forsythia [T. forsythia], Prevotella intermedia [P. intermedia], Porphyromonas gingivalis [P. gingivalis], Aggregatibacter actinomycetemcomitans [A. actinomycetemcomitans]), and immunological (interleukin [IL]-6, IL-1β, tumor necrosis factor-alpha [TNF-α]) outcomes were assessed at baseline and 3-month follow-up.

Results: Mean changes between baseline and 3-month follow-up in peri‑implant clinico-radiographic parameters were significantly different between control (PI: 12.42±21.80%; BOP: 12.10±19.30%; PD: 0.45±0.41 mm; CBL: 1.10±1.02 mm) and test groups (ICG-mediated PDT [PI: 26.55±25.80%; BOP: 28.77±29.24%; PD: 0.84±0.62 mm; CBL: 1.98±1.85 mm] and MB-mediated PDT [PI: 27.24±26.15%; BOP: 27.71±28.16%; PD: 0.85±0.63 mm; CBL: 1.95±1.80 mm]), however comparable differences were observed in peri‑implant PI, BOP, PD, and CBL between group-II and group-III participants (p>0.05). The proportions of T. forsythia were significantly reduced in group-II (4.78 × 10 colony-forming unit per milliliter [CFU/mL]) and group-III (4.76 × 10 CFU/mL) as compared to group-I (-4.40 × 10 CFU/mL) at 3-month follow-up (p = 0.02). No statistically significant differences were observed between the study groups regarding the proportions of the other assessed target bacterial species. For IL-6 (group-I: 210±108; group-II: 298±165; group-III: 277±121 pg/mL; p = 0.03), IL-1β (group-I: 101±95; group-II: 84±98; group-III: 86±74 pg/mL; p = 0.02), and TNF-α (group-I: 336±121; group-II: 385±210; group-III: 366±198 pg/mL; p = 0.03) peri‑implant sulcular fluid [PISF] levels, all three study groups demonstrated statistically significant reduction at 3-month follow-up.

Conclusions: ICG-mediated and MB-mediated adjunctive PDT showed statistically significant improvements in peri‑implant clinical, radiographic, microbiological, and immunological parameters as compared to conventional MD alone at 3-month follow-up among diabetics with pi-M. However, comparable outcomes were demonstrated by ICG-mediated and MB-mediated adjunctive PDT regarding the assessed peri‑implant parameters.

Citing Articles

Revolutionizing oral care: Reactive oxygen species (ROS)-Regulating biomaterials for combating infection and inflammation.

Zhao W, Zhang Y, Chen J, Hu D Redox Biol. 2024; 79():103451.

PMID: 39631247 PMC: 11664010. DOI: 10.1016/j.redox.2024.103451.


Bactericidal Effect of Different Photochemical-Based Therapy Options on Implant Surfaces-An In Vitro Study.

Wenzler J, Wurzel S, Falk W, Bocher S, Wurzel P, Braun A J Clin Med. 2024; 13(14).

PMID: 39064253 PMC: 11278127. DOI: 10.3390/jcm13144212.


Efficacy of adjunctive photodynamic therapy to conventional mechanical debridement for peri-implant mucositis.

Guo J, Chen X, Xie H, Li T BMC Oral Health. 2024; 24(1):464.

PMID: 38627721 PMC: 11020816. DOI: 10.1186/s12903-024-04198-6.


Influence of Photosensitizer on Photodynamic Therapy for Peri-Implantitis: A Systematic Review.

Schweigert T, Afonso J, da Palma R, Oliveira-Silva I, Silva C, Jirjos E Pharmaceutics. 2024; 16(3).

PMID: 38543201 PMC: 10975756. DOI: 10.3390/pharmaceutics16030307.